Search
ACR-16
go.drugbank.com/drugs/DB05371InvestigationalACR-16 is a dopamine stabilizer. ACR-16 is also being studied in other psychiatric and neurologic diseases. … ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington
ISIS 113715
go.drugbank.com/drugs/DB05506InvestigationalISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measure...
S-8510
go.drugbank.com/drugs/DB06504ExperimentalS-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
Navitoclax
go.drugbank.com/drugs/DB12340InvestigationalIt is a substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying.
Gabexate
go.drugbank.com/drugs/DB12831InvestigationalGabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines.
Davamotecan pegadexamer
go.drugbank.com/drugs/DB05899InvestigationalEP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound [camptothecin].
Categories: Compounds used in a research, industrial, or household settingEvofosfamide
go.drugbank.com/drugs/DB06091InvestigationalTH-302 is a nitroimidazole-linked prodrug of a brominated derivative of an isophosphoramide mustard previously used in cancer drugs such as ifosfamide, cyclophosphamide, and glufosfamide. … TH-302 is a novel cancer therapeutic specifically activated under the low oxygen or "hypoxic" conditions typical of solid tumor cancer cells.